University of Chicago
Dr Marina Chiara Garassino was the Chief of the Thoracic Oncology Unit at Istituto Nazionale dei Tumori, Milan, Italy. She led the strategy for clinical and translational research in advanced and locally advanced NSCLC, SCLC, mesothelioma and thymic malignancies. Istituto Nazionale dei Tumori in Milan is the most important Comprehensive Cancer Center in Italy, and one of the most important in Europe.
She has done research in precision medicine and in immuno-oncology.
Research interests: NSCLC, SCLC, mesothelioma and development of biomarkers.
She has contributed to over 200 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology. She has delivered many presentations at international congresses, including ASCO, AACR, WCLC, ESMO.
In the last year she was the Principal Investigator of TERAVOLT a global registry of patients with COVID-19 and thoracic malignancies.
Her education includes a degree and further specialization in Medical Oncology at Università degli Studi, in Milan. She completed her training with an ESMO Clinical fellowship in 2009 at Christie's Hospital in Manchester (UK). She was a member of the EMA SAG (Scientific Advisory Group).
She achieved a Master Degree at University of Economics “Luigi Bocconi”.
Dr Garassino is serving on several ESMO Committees (Public Policy extended Committee, Press Committee, Women for Oncology Committee, Lung Cancer faculty, Membership Committee) and as Chair of the National Societies Committee, from 2019. She is in the Scientific Committee of ASCO Annual Meeting (2019-2021) and AACR annual Meeting.
BMS (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal and Institutional; Boehringer Ingelheim Italia S.p.A (Individual(s) Involved: Self): Other Financial or Material Support, Personal and Institutional; Celgene (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal and Institutional; Daiichi Sankyo (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal; Eli Lilly (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal and Institutional; Ignyta (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal and Institutional; Incyte (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal and Institutional; Inivata (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal and Institutional; MedImmune (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal and Institutional; Merck (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal; Mirati (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal; MSD International GmbH (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal and Institutional; Novartis (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Other Financial or Material Support, Personal and Institutional, Personal and Institutional; Pfizer (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal and Institutional; Regeneron (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal; Roche (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal and Institutional; Seattle Genetics (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal; Takeda (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Personal and Institutional; Tiziana, Foundation Medicine, Glaxo Smith Kline, Spectrum Pharmaceuticals, AIRC, AIFA, Italian Moh, TRANSCAN, Research Fundings (Individual(s) Involved: Self; Clinical Condition: Oncology): Institutional, Other Financial or Material Support
Thursday, August 25, 2022
1:35 PM – 3:30 PM
Thursday, August 25, 2022
2:00 PM – 2:20 PM
Thursday, August 25, 2022
3:10 PM – 3:30 PM
Friday, August 26, 2022
12:10 PM – 1:50 PM
Friday, August 26, 2022
1:30 PM – 1:50 PM
Friday, October 14, 2022
3:35 PM – 5:10 PM
Friday, October 14, 2022
4:00 PM – 4:20 PM
Friday, October 14, 2022
4:50 PM – 5:10 PM
Saturday, October 15, 2022
8:20 AM – 9:55 AM
Saturday, October 15, 2022
8:55 AM – 9:15 AM
Saturday, October 15, 2022
9:35 AM – 9:55 AM
Thursday, November 10, 2022
12:40 PM – 2:10 PM
Thursday, November 10, 2022
1:05 PM – 1:25 PM
Thursday, November 10, 2022
1:45 PM – 2:10 PM
Friday, November 11, 2022
9:00 AM – 11:00 AM
Friday, November 11, 2022
9:25 AM – 9:45 AM
Friday, November 11, 2022
10:35 AM – 11:00 AM
Friday, November 11, 2022
12:20 PM – 2:10 PM
Friday, November 11, 2022
12:45 PM – 1:05 PM
Friday, November 11, 2022
1:32 PM – 1:39 PM
Friday, November 11, 2022
1:39 PM – 1:45 PM
Friday, November 11, 2022
1:45 PM – 2:10 PM